Skip to main content
. 2016 Aug 2;7(37):59945–59956. doi: 10.18632/oncotarget.11007

Figure 6.

Figure 6

A. 5-year CSSs in all RCC patients with lymph node ≥15 and <15. B. 5-year CSSs in node-negative RCC patients with lymph node ≥15 and <15. C. 5-year CSSs in node-positive RCC patients with lymph node ≥15 and <15. D. 5-year CSSs in all LCC patients with lymph node ≥11 and <11. E. 5-year CSSs in node-negative LCC patients with lymph node ≥11 and <11. F. 5-year CSSs in node-positive LCC patients with lymph node ≥11 and <11. G. 5-year CSSs in all patients with lymph node ≥12 and <12. H. 5-year CSSs in all node-negative patients with lymph node ≥12 and <12. I. 5-year CSSs in all node-positive patients with lymph node ≥12 and <12.